License Grant. Urovant hereby grants to Sunovion a non-exclusive license, with the right to grant sublicenses, under any intellectual property rights owned or controlled by Urovant, including with respect to the Work Product, solely to enable Sunovion to perform the Services. Except as otherwise expressly provided herein, nothing in this Agreement is intended to grant to either Party any rights under any intellectual property right of the other Party.

License Grant. Subject to the terms and conditions of this Agreement, [[Aravive:Organization]] hereby grants [[3D Medicines:Organization]] an exclusive (even as to [[Aravive:Organization]] except as provided in Section 2.1(b) below) license, with the right to sublicense (solely as provided in Section 2.1(c)), under the [[Aravive:Organization]] Technology, to Develop, Manufacture and have Manufactured (solely in accordance with Section 7.2), distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise Commercialize Licensed Products in the Field in the [[3D Medicines:Organization]] Territory. For clarity, no rights shall be granted to [[3D Medicines:Organization]] under this Section 2.1(a), with respect to the Development, Manufacture or Commercialization of any product containing the Licensed Compound together with one or more Drug Substances other than the Licensed Compound or use in combination with one or more Drug Substances other than the Licensed Compound. As consideration for the foregoing license and access to and transfers of know-how under this Agreement, [[3D Medicines:Organization]] will make certain payments to [[Aravive:Organization]] as set out in, and subject to the terms and conditions of, Article 8.

License Grant. Subject to the limitations and other terms and conditions set forth in this Agreement including those reserved by Institute in [Section 2.5(a)], Institute hereby grants to Licensee an exclusive, royalty-bearing, sublicenseable (in accordance with [Article 3]) license in, to and under # the Patent Rights and the Know-How Rights, and # Institute’s interest in any patents and patent applications owned jointly by Licensee and Institute, to make, use, Sell, offer for Sale and import Licensed Products, and to practice Licensed Methods, in each case with respect to # Allogeneic CTL Products in the Territory in the Licensed Field, # solely with respect to HPV-Specific CTL Products, EBV-Specific Autologous Products, and Autologous CTL Products in the Licensed Field, and # solely following ​ arising from the ​.

License Grant. Subject to the terms and conditions of this Agreement, upon payment of the Upfront License Payment in [Section 7.1], [[NanoTx:Organization]] hereby grants to PLUS an irrevocable, perpetual, exclusive, fully paid-up, with the right to sublicense in accordance with Section 2.2, license to make, have made, use, have used, Develop, have Developed, Commercialize, have Commercialized, import and otherwise exploit the Licensed Patents, Know-How and Licensed Technology (the “License Grant”). The License Grant includes the right to utilize the Licensed Patents, Know-How or Licensed Technology to develop derivative products, including but not limited to adding a drug to the liposomal delivery system. In partial consideration for the License Grant, PLUS agrees to pay the Milestone Payments and Royalties as and when due in accordance with the terms of this Agreement.

License Grant. Subject to the reservations of rights set forth in Paragraph 2.2, BCM hereby grants to LICENSEE an exclusive, worldwide, sublicensable license under the Patent Rights and Subject Technology, to make, have made, use, market, sell, offer to sell, lease and import Licensed Products in the Field.

License Grant. As of the Effective Date, Novo shall grant to TransTech an exclusive (even as to Novo), royalty-bearing license, under the Novo Intellectual Property, to discover, Develop, Manufacture, have Manufactured, use and Commercialize in the Field in the Territory Licensed Products.

License Grant. Subject to the terms of this Agreement, ​, [[Agenus:Organization]] hereby grants Betta a royalty-bearing, non-transferable (except in accordance with [Section 14.3]), sublicenseable (subject to Section 2.5) license or sublicense, as applicable, under the Licensed IP solely to Develop, Manufacture and Commercialize Licensed Products in the Field and in the Territory (the “License”). Subject to Section 2.2 and Section 2.3, the License will be # exclusive (even as to [[Agenus:Organization]] and its Affiliates) with respect to the Licensed Patent Rights and the Licensed Know-How that are exclusively licensed to [[Agenus:Organization]] or owned by [[Agenus:Organization]], and # non-exclusive with respect to the Licensed Patent Rights and Licensed Know-How that are non-exclusively licensed to [[Agenus:Organization]].

#[[Peraso:Organization]] hereby grants to [[Intel:Organization]] an unlimited, irrevocable, perpetual, non-terminable, fully paid up, royalty-free, freely transferrable (as set forth in Section 16.3 below), freely sublicensable (through multiple tiers of sublicensees), exclusive (even as to [[Peraso:Organization]], as set forth in [Section 2.2] below) right and license, under all of [[Peraso:Organization]]’s applicable Intellectual Property Rights in and to the Licensed Technology, to develop, make, make for others, have made, perform, have performed, perform for others, use, operate, sell, offer for sale, import, and export products embodying or using the Licensed Technology, and to otherwise freely commercialize and exploit the Licensed Technology in the Territory, as [[Intel:Organization]] deems fit in its sole and absolute discretion.

License Grant. Subject to the terms and conditions of this Agreement, including [Section 8.3, FWB] hereby grants to AzurRx an exclusive (even as to FWB and its Affiliates), non-transferable (except as permitted under [Section 16.2]), sublicensable through multiple tiers (solely in accordance with Section 8.1.2) license under: # the FWB Background IP, # FWB’s rights to any Program IP, and # any other intellectual property Controlled by FWB as of the Effective Date or at any time during the Term and necessary or reasonably useful to Exploit the Existing Product (collectively the “Licensed IP”), in each case ((i) - (iii)), to Develop and have Developed, make, have made, use, sell, have sold, import, export and Exploit the Product in the Field in the Territory.

License Grant. Subject to the terms and conditions of this Agreement, including Section 8.3, AzurRx hereby grants to FWB a worldwide, non-exclusive, royalty-free, perpetual, irrevocable license under the Program IP and any other intellectual property owned by AzurRx and incorporated into the Product for the Exploitation of such Product during the Term, solely for use outside the Field in the Territory, and if this Agreement is terminated rather than expires, then such license shall be for the Exploitation of the Product both inside and outside the Field, in the Territory.